Feasibility of the Application of a new Six-month Treatment for multidrug-resistant tuberculosis (MDR-TB) patients in France (FAST-MDR)
Key facts
- Where
- Amiens, Bordeaux, Briis-sous-Forges, Lyon Cedex 04, Montpellier Cedex 5, Nantes, Nice, Paris, Paris Cedex 18, Rennes, Schiltigheim és Toulouse, FranciaországSee the 12 sites
- Phase
- 3. fázis
Where in Franciaország
- Centre Hospitalier Universitaire Amiens - PicardieAmiens, FranciaországTaking people
- Centre hospitalier Universitaire de BordeauxBordeaux, FranciaországTaking people
- Centre hospitalier de BlignyBriis-sous-Forges, FranciaországTaking people
- Hospices Civils De LyonLyon Cedex 04, FranciaországTaking people
- Centre Hospitalier Universitaire De MontpellierMontpellier Cedex 5, FranciaországTaking people
- Centre Hospitalier Universitaire de NantesNantes, FranciaországTaking people
- Centre Hospitalier Universitaire de NiceNice, FranciaországTaking people
- Assistance Publique Hopitaux de ParisParis, FranciaországTaking people
- Assistance Publique Hopitaux De ParisParis Cedex 18, FranciaországTaking people
- Centre Hospitalier Universitaire de RennesRennes, FranciaországTaking people
- Les Hopitaux Universitaires De StrasbourgSchiltigheim, FranciaországTaking people
- Centre Hospitalier Universitaire de ToulouseToulouse, FranciaországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Assistance Publique Hopitaux De Paris
- Trial code
- EU 2024-512763-32-00
- Record updated
- 2025. július 31.
- Original description
Determine if BPaLM has non-inferior effectiveness at 18 months after study treatment start compared to the long, conventional MDR-TB regimens assessed in an historical cohort of patients treated in France in 2006-2022.Read full original descriptionShow less
Determine if BPaLM has non-inferior effectiveness at 18 months after study treatment start compared to the long, conventional MDR-TB regimens assessed in an historical cohort of patients treated in France in 2006-2022.
Inclusion: Is 18 years old or more; Is affected by bacteriologically- or molecularly-confirmed tuberculosis, due to strains of M. tuberculosis resistant to rifampicin (with or without resistance to isoniazid) according to a rapid molecular test; Is willing and able to give informed consent to be enrolled in the research project (signed or witnessed consent if the patient is illiterate); Is willing to use effective contraception: women with childbearing potential must agree to use effective contraception, unless their partner has had a vasectomy, for the duration of study treatment and up to 6 months after the end of study treatment; men who have not had a vasectomy must agree to use effective contraception for the duration of study treatment and up to 3 months after the end of study treatment; Is affiliated to a social security system (as beneficiary) or has state medical aid (AME) or has an ongoing demand for AME or has an ongoing demand for an emergency medical care (dispositif de soins d'urgence, as applicable for tuberculosis).
Exclusion: Is unable to take oral drugs; Is taking or needs to take contraindicated medications in association with investigational medicinal products; Has any other condition (social or medical) which, in the opinion of the site investigator, would make the study participant unsafe; Has known allergies, hypersensitivity or intolerance or any other medical condition and contra indications to any drug of the regimen; Has ≥500 msec QTcF interval on any ECG taken at screening or baseline visits, or has any cardiac risk factor for severe arrhythmia; Is already on a MDR/RR-TB treatment regimen since 4 weeks or more, and has no need to change the treatment regimen (i.e. adverse events, treatment failure); Has significant and uncorrectable lab abnormalities at baseline: haemoglobin ≤7.9 g/dL, platelet count <75 000/mm3; absolute neutrophil count <1 000/ mm3; potassium <3.0 mEq/L; serum creatinine >3 x upper level of normality (ULN); alanine aminotransferase (ALT) ≥3 x ULN; Has peripheral neuropathy of grade 3 or 4 (CTCAE scale); Is known to be pregnant or is unwilling or unable to stop breastfeeding an infant; Unwilling to comply to study procedures, at the clinician appreciation; Has proven or likely resistance to bedaquiline, clofazimine, linezolid, pretomanid or moxifloxacine, or has had exposure (for 30 days or more) in past five years to bedaquiline, clofazimine, delamanid, linezolid, or pretomanid; Has severe extrapulmonary TB, including meningo-encephalitis, brain abscess, osteo-arthritis, osteomyelitis; Is concurrently participating in another trial of any medicinal product.